CanSino Biologics Inc. (CASBF)

2.1000 0.0000 (0.00%) At close: 11:28AM EDT

CanSino Biologics Inc.

401-420, Biomedical Park
4th Floor 185 South Avenue TEDA West District
Tianjin 300457
China
86 022 5821 3600
https://www.cansinotech.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 1,494

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Xuefeng Yu Ph.D.	Co-Founder, Executive Chairman, CEO & GM	N/A	N/A	1965
Dr. Tao Zhu Ph.D.	Co-Founder, Deputy GM, Chief Scientific Officer & Executive Director	N/A	N/A	1974
Dr. Dongxu Qiu MBA, Ph.D.	Co-Founder, Executive VP, Deputy GM & Executive Director	N/A	N/A	1961
Dr. Shou-Bai Chao Ph.D.	COO, Deputy GM & Executive Director	N/A	N/A	1964
Ms. Jing Wang	Chief Commercial Officer, Deputy GM & Executive Director	N/A	N/A	1981
Mr. Chunlin Xin	Senior Director of New Technology Department	N/A	N/A	N/A
Mr. Yonghui Wu	Vice President of Marketing	N/A	N/A	N/A
Mr. Jin Cui	Board Secretary	N/A	N/A	1987
Mr. Ming King Chiu FCIS, FCS	Joint Company Secretary	N/A	N/A	1977

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Corporate Governance

CanSino Biologics Inc.’s ISS Governance QualityScore as of April 29, 2024 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.